Skip to main content

Anti-aging Technologies Based on Real Science and Developed by Real Scientists

Lead Product YuuthTM – Rebooting the Genetic Program to Restore Youthful Beauty

Ponce Therapeutics is using advanced, proprietary technologies to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead programs utilize proprietary, state-of-the-art biotechnology platforms to restore the youthful balance of aged or “senescent” and young cells in the skin, targeting the senescent cells for elimination. This provides a “reboot” of one’s genetic program to turn the clock on one’s skin back to its youthful exuberance.

Proprietary Platform

Targeting Senescent Cells for Elimination

Elimination of pro-inflammatory senescent cells has been shown to suppress cancer and rejuvenate tissues by restoring stem cell niches to their healthy state.

Ponce Therapeutics Gene Therapy

Clinical Pipeline

Development of our lead program, PT-001mn

Lead program, PT-001mn, to deliver p16-directed riCasp9 to keratinocytes in treating Bowen’s lesions using proprietary delivery technology.

July 25, 2022 in K2 BioLabs, Ponce Therapeutics, Portfolio, Rapha Capital Management

Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma’s Nano-in™ and No-Pass Mimic™ Nanoparticle Technologies in Anti-Aging and Other Products Initially for Skin

Ponce Therapeutic's ("Ponce") lead product, ReBeaut™, is a microneedle patch containing nanoparticles carrying its proprietary ApoptiCIDe™ cell elimination gene therapy technology targeting senescent keratinocytes and fibroblasts in the skin Speratum Biopharma ("Speratum")…
Read More
June 14, 2021 in K2 BioLabs, Ponce Therapeutics, Portfolio, Rapha Capital Management

New Biotechnology Research Accelerator Launches in Houston

K2-BioLabs offers “big company” resources that accommodate “small company” budgets Rapha Portfolio Company PONCE Therapeutics, Inc. is an investor and the first tenant of K2 Bio Houston, TX, June 14,…
Read More